Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Jennifer B. Damico, Senior Vice President and Controller at Pfizer Inc. (NYSE:PFE), recently made several transactions involving the company’s stock, according to a Form 4 filed with the Securities and Exchange Commission. On March 4, Damico sold 2,500 shares of Pfizer common stock at a price of $25.93 per share, totaling $64,825. The transaction occurred as Pfizer’s stock trades near its 52-week low of $24.48, with the pharmaceutical giant currently valued at $149 billion.
In addition to the sale, Damico also acquired 5,583 shares of common stock on the same day. This acquisition was part of a grant of restricted stock units, which are subject to specific vesting requirements, and was made at no cost per share.
The transactions leave Damico with a total of 11,850 shares of Pfizer common stock. The filing also highlights a previous transaction on February 27, where 749 shares were withheld to satisfy tax obligations upon the vesting of restricted stock units, at a price of $26.10 per share. Notably, Pfizer maintains a strong 6.63% dividend yield and has consistently paid dividends for 55 consecutive years. InvestingPro analysis suggests the stock is currently undervalued, with multiple growth catalysts identified in their comprehensive Pro Research Report.
In other recent news, Pfizer’s latest developments have captured the attention of investors and analysts alike. A German court ruled that Pfizer, along with its partner BioNTech (NASDAQ:BNTX), infringed on Moderna (NASDAQ:MRNA)’s COVID-19 vaccine patent, requiring them to disclose profits and potentially compensate Moderna. In a separate move, Pfizer is considering relocating its overseas manufacturing to the U.S. amid tariff threats from the Trump administration, although no specific plans have been announced. Analyst firm Bernstein SocGen Group has adjusted its price target for Pfizer shares, reducing it from $32.00 to $30.00 while maintaining a Market Perform rating, highlighting cautious optimism about Pfizer’s strategic initiatives in research and development.
Additionally, Pfizer has entered a clinical trial collaboration with Summit Therapeutics (NASDAQ:SMMT) to evaluate the combination of Summit’s ivonescimab with Pfizer’s antibody drug conjugates for treating multiple solid tumor types. This partnership aims to advance cancer treatment options and enhance patient care. The collaboration underscores Pfizer’s ongoing efforts to innovate in oncology and strengthen its position in the pharmaceutical industry. These recent developments reflect Pfizer’s strategic maneuvers in a rapidly evolving healthcare landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.